Home > Boards > US Listed > Medical - Drugs >

AxoGen, Inc. (AXGN)

Add AXGN Price Alert      Hide Sticky   Hide Intro
Moderator: Prudent Capitalist
Search This Board: 
Last Post: 10/30/2018 12:44:33 PM - Followers: 16 - Board type: Free - Posts Today: 0

 A Cutting Edge Regenerative Medicine Technology Company Offers Compelling Alternatives for Patients and Physicians in the Treatment of Peripheral Nerve Repair and Reconstruction.

The company's portfolio of regenerative technology for peripheral nerve repair provides it an opportunity to participate in a market estimated to be $1 billion.

AxoGen, Inc. (OTCBB: AXGN) is a leading regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance(R) Nerve Graft, the only commercially available allograft nerve for bridging peripheral nerve discontinuities (a gap created when the nerve is severed) of up to 70mm in length.

AxoGen's portfolio also includes AxoGuard(R) Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard(R) Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's, principal executive office and operations are located in Alachua, FL.


First Quarter Highlights

·On May 14, 2012 AxoGen, Inc Record First Quarter 2012 Revenues

·Revenues were $1.65 million, a 47% Increase from First Quarter 2011

·Gross profits increased 55% over First Quarter 2011 to a record $1.21 million

·Gross profit margins improved to 73% compared to 70% in 2011


Management Team / Board of Directors

Karen Zaderej-Chief Executive Officer Ms. Zaderej has served as President, Chief Executive Officer and a member of the board of directors of AxoGen, Inc. since September 2011. Karen has served as Chief Executive Officer and as a member of the board of directors of AxoGen Corporation since May 2010. Karen joined AxoGen in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Karen worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies build and execute successful commercialization plans. From 1987 to 2004, Karen worked at Ethicon, Inc., a Johnson & Johnson company, where she held senior positions in marketing, business development, research & development, and manufacturing. Karen has a MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University

Gregory G. Freitag, Chief Financial Officer and Director Mr. Freitag, J.D., CPA, has been Chief Financial Officer of AxoGen, Inc. (formerly LecTec Corporation) and a member of its board of directors since June 2010. Greg has also served as Chief Financial Officer and a member of the board of directors of AxoGen Corporation, AxoGen, Inc.'s wholly owned subsidiary, since September 2011. From June 30, 2010 to September 2011 Gregory was Chief Executive Officer of LecTec Corporation, having resigned such position pursuant to the reverse merger between LecTec Corporation (renamed AxoGen Inc.) and AxoGen Corporation. Greg in May 2009 was cofounder, and continues as a principal, of FreiMc, LLC, a consulting and advisory firm that provides strategic guidance and business development advisory services related to the life sciences and healthcare markets. Prior to founding FreiMc, LLC Greg was the Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc., from January 2006 to May 2009. From July 2005 to January 2006, Greg worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, Greg was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company, from March 2000 until its sale in early 2005. Greg was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd., a public point of care diagnostic company, from December 1995 to March 2000. Prior to that time, Greg practiced corporate/securities law in Minneapolis, Minnesota. Greg is also a director of Pressure BioSciences, Inc., a publicly traded life sciences company focused on the development of a novel, enabling technology called Pressure Cycling Technology.

Jill F. Schiaparelli, Senior Vice President, Business Strategy & Marketing-Ms. Schiaparelli has served as AxoGen's Senior Vice President, Business Strategy & Marketing since February 2012 and oversees the business strategy, analytics and marketing functions. Jill brings to AxoGen more than 20 years of global business experience in the medical device, biosurgery, and investment banking industries with leadership roles in marketing, new product development, commercial strategy and analytics. From January 2011 to February 2012 and from June, 2007 to December 2008, Jill was employed by JS Strategic Partners, LLC, a consulting firm she founded to provide business strategy, commercialization and marketing services to biotechnology companies and health care providers. From December 2008 to December 2010, Jill was the Vice President, Commercial Strategy & Business Development for ApaTech, a venture-back global orthopedic graft company based in the UK and later acquired by Baxter Healthcare. From 1996 to 2007, Jill was employed by Johnson & Johnson family of companies where she held several senior positions in strategic marketing, marketing, sales operations and healthcare analytics within the Ethicon Endo-Surgery, Ethicon and Healthcare Systems operating companies. Her appointments included Global Director, Obesity Strategic Marketing, Director Emerging Technologies (biosurgery & cardiovascular), Product Director for Tissue Regeneration and Director of National Account Operations. Prior to working in the healthcare industry, Jill was in the investment banking industry. As a Vice President with Integrated Resources, she had responsibility for their aircraft and equipment leasing portfolio and was a fiduciary for several investment funds. Jill received her MBA from the Stern School of Business at New York University and a BS in Business Administration from Boston University.

John P. Engels-Vice President-Mr. Engels has served as Vice President of AxoGen, Inc. since September 2011. John is a co-founder of AxoGen Corporation and has served as Vice President since November 2002, providing operational and financial leadership and managing AxoGen's strategic and product development partnerships. From 1999 to 2002, John worked as a consultant for the University of Florida, Saffron Hill Ventures and PA Early Stage Partners, among other companies. John also worked from 1993 to 1997 for CACM, a boutique investment banking firm. John holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA in Political Science from the University of Chicago.


Mark Friedman, Ph.D., Vice President of Regulatory Affairs and Quality Assurance-Dr. Friedman has served as Vice President of Regulatory Affairs for AxoGen, Inc. since September 2011. He has served as Vice President of Regulatory Affairs and Quality Assurance since June 2011 and as Director of Quality Assurance and Regulatory Affairs from September 2006 to June 2011 for AxoGen Corporation. Prior to joining AxoGen, Mark held several regulatory and quality leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance from 1997 to 1998 and Vice President of Quality and Regulatory from 1998 to 2001 and from 2004 to 2005. Mark also worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory from 2001 to 2004 and as Vice President of Operations in 2004. AtriCure acquired Enable Medical in 2005. Mark has over 24 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with startup medical product firms. Mark has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati.


Brad Hedger-Vice President of Sales-Mr. Hedger has served as Vice President of Sales for AxoGen, Inc. since September 2011 and as Vice President of Sales of AxoGen Corporation since January 2011. From September 2008 to December 2010, Brad served as President and Chief Executive Officer of Patient Care, a company founded by Brad, which distributed products directly for AxoGen and DePuy Spine, Inc. in the states of Colorado and Wyoming. Brad served as Director of Upper Extremity Trauma Sales for the Orthopaedics division of Stryker Corporation, a publicly traded medical technology company, from March 2006 to September 2008. Prior to that, Brad held direct sales and regional management positions for 13 years at Synthes Inc., an orthopedic trauma company. Brad has a BS in Political Science and Computer Science from Cornell College


Erick DeVinney, Director of Clinical Research-Mr. DeVinney has served as Director of Clinical Research for AxoGen, Inc. since September 2011. He has served as Director of Clinical Research for AxoGen Corporation since April 2007. Erick has over eight years of experience in the successful planning and management of clinical trials. He has diverse background including research at a large academic facility and management of clinical operations for a medical device and pharmaceutical company. Erick has been involved in clinical research at Medical College of Virginia Hospitals, National Clinical Research, PRA International, and Angiotech. He has been involved in the successful submission of eight IDE or NDA applications as well as numerous 510(k)s. He has a BS in Chemistry from Virginia Commonwealth University.

Mike Donovan, Director of Operations-Mr. Donovan has served as Director of Operations for AxoGen, Inc. since September 2011. He has served as Director of Operations for AxoGen Corporation since January 2011. From 1988 to 2010, Mike held positions at Zimmer Holdings in Manufacturing, Continuous Improvement, Quality Assurance and Sterilization including Director of Manufacturing from 2002 to 2010. Mike has a BS in Chemical Engineering and an MBA from the University of Akron


David Hansen, Corporate Controller-Mr. Hansen has served as Corporate Controller of AxoGen, Inc. since September 2011 and as Corporate Controller of AxoGen Corporation since June 2006. From June 2005 to June 2006, Dave was Vice President of Finance-Corporate Controller and Treasurer of Perma-Fix Environmental Services, Inc., a publicly traded environmental services company, and held other corporate and regional accounting positions at Perma-Fix Environmental Services from 1995 to 2005. Dave was also Controller at Kraft Foodservice, Inc. from 1994 to 1995 and held other accounting and procurement positions at Kraft Foodservice, Inc. from 1985 to 1994. Dave has over 20 years of experience in senior financial positions at both publicly traded and private companies. Dave holds a Bachelor of Business Administration degree in Accounting from the University of Oklahoma.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AXGN News: Statement of Changes in Beneficial Ownership (4) 11/15/2018 05:21:48 PM
AXGN News: Statement of Changes in Beneficial Ownership (4) 11/15/2018 05:19:38 PM
AXGN News: Statement of Changes in Beneficial Ownership (4) 11/15/2018 05:17:02 PM
AXGN News: AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018 11/06/2018 07:00:00 AM
AXGN News: Statement of Changes in Beneficial Ownership (4) 11/05/2018 07:50:04 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#172  Sticky Note Overweight rating and $43 Price Target maintained by Prudent Capitalist 10/30/18 12:44:32 PM
#172   Overweight rating and $43 Price Target maintained by Prudent Capitalist 10/30/18 12:44:32 PM
#171   Load zone! Bruce the Stock Guy 10/27/18 11:23:21 AM
#170   And now down to $32.00... and it'll keep falling. dog turd cannon 10/24/18 11:22:50 PM
#169   I don't see it at all. dog turd cannon 10/10/18 05:35:01 PM
#168   :-) 3-45 ='s free shares. Tearex 09/15/18 10:56:12 PM
#167   It would appear reloading in that range was premature. dog turd cannon 09/12/18 04:46:48 PM
#166   No. My money is better spent elsewhere. There dog turd cannon 09/09/18 12:31:57 AM
#165   AXGN..I wont sell this beast until the 100’s.. Bruce the Stock Guy 09/04/18 03:27:51 PM
#164   Hope you reloaded down in the $36 - Prudent Capitalist 09/04/18 12:40:11 PM
#163   +3.93%. Nice day here for AXGN, with Prudent Capitalist 08/23/18 04:31:08 PM
#162   AXGN is holding up nicely here, and is Prudent Capitalist 08/21/18 03:07:52 PM
#161   Cheers! $$$ Tearex 08/07/18 03:50:08 PM
#160   Down from 50+ to 39... ouch. dog turd cannon 08/01/18 04:56:46 PM
#158   Wow, the guy that posted about $AXGN at dog turd cannon 08/01/18 04:54:06 PM
#157   What are you expecting tonight Lynx5100 08/01/18 07:06:54 AM
#156   AXGN..Beast! Bruce the Stock Guy 08/01/18 06:28:14 AM
#155   I spoke to investor relations on this this Lynx5100 07/31/18 04:48:49 PM
#154   No, not at all. dog turd cannon 07/30/18 10:38:30 AM
#153   60%+ in 8-12 months isn't much of a jimmybob 07/29/18 02:31:35 PM
#152   I am out already. Even if you are dog turd cannon 07/29/18 02:01:00 PM
#151   Not at all likely. AXGN should continue Prudent Capitalist 07/23/18 02:09:59 PM
#150   Overpriced. Expecting a long deep fall. manisero66 07/23/18 08:27:39 AM
#149   $80-120 in the next 12-18 months jimmybob 07/19/18 02:17:12 PM
#148   $AXGN $56.20s what a monster jimmybob 07/19/18 02:16:48 PM
#147   Anybody looked at LMAT? Thoughts? rajaram46 07/19/18 01:28:03 PM
#146   AXGN..SAVAGE! Bruce the Stock Guy 07/17/18 11:04:04 PM
#145   AXGN..Monster! Bruce the Stock Guy 07/08/18 06:13:01 PM
#144   It is time to sell. There is too dog turd cannon 07/06/18 08:48:50 PM
#143   ROcking! and Rolling! jimmybob 07/06/18 10:22:22 AM
#142   Another new all time high here today for Prudent Capitalist 07/06/18 09:59:10 AM
#141   Axgn isn't even close to being done. Thedeadman 06/28/18 10:37:49 PM
#140   AxoGen price target raised to $70 from $45 jimmybob 06/26/18 08:51:08 AM
#139   Way too early to sell any of my Prudent Capitalist 06/11/18 04:33:21 PM
#138   It's just under $50.00 now. Soon it'll be dog turd cannon 06/11/18 01:31:02 PM
#137   haha :) jimmybob 05/31/18 08:39:13 PM
#136   So much for that new $45 price target. Prudent Capitalist 05/31/18 02:09:43 PM
#135   Congrats! No competition... AXGN is on an empty jimmybob 05/31/18 01:38:18 PM
#134   $AXGN $49s dude jimmybob 05/31/18 11:21:46 AM
#133   Another new all time high here today. Prudent Capitalist 05/31/18 10:33:47 AM
#132   AXGN..Beast.. Bruce the Stock Guy 05/29/18 12:59:59 PM
#131   AxoGen, Inc. Announces Repayment in Full of its Prudent Capitalist 05/29/18 12:53:48 PM
#130   A monster.... jimmybob 05/04/18 03:59:41 PM
#129   AxoGen remains a 'best in medtech story,' says Jefferies jimmybob 05/01/18 08:26:00 AM
#128   AxoGen price target raised to $45 from $37 jimmybob 05/01/18 07:14:42 AM
#127   It never will pull back, and will continue Prudent Capitalist 04/23/18 10:01:00 AM
#126   AXGN..Wish I had bought more earlier..This stock is Bruce the Stock Guy 04/22/18 12:30:14 PM
#125   AXGN..Awesome buys..I’m in much much higher(embarrassed to say)..Gl! Bruce the Stock Guy 03/22/18 11:49:50 AM
#124   Yes it is. Has been a great Prudent Capitalist 03/22/18 11:34:26 AM
#123   $AXGN..So STRONG! Bruce the Stock Guy 03/22/18 08:40:55 AM
#122   $100<<<<AXGN..I can see it..Its a one of kind company! Bruce the Stock Guy 03/01/18 11:16:12 AM